IMGN News and Press, ImmunoGen Inc. From 12/12/21

Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation S...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatm...

The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In ...

ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints. A pivotal confirmatory study using mirvetuximab, known as MIRASOL, is expected to have results out by Q3 of 2022. This c...

ImmunoGen (NASDAQ:IMGN) has priced its public offering of ~11.6M common shares at $6.60/share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to ~27.4M shares of common stock at $6.59/share. Expected gross proceeds are $257.1M. Underwriters' ove...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60 per share, before underwriting d...

Shares of ImmunoGen (NASDAQ: IMGN) , a small-cap specialist in antibody-drug conjugates (ADCs), were up a healthy 13.1% as of 12:17 p.m. ET Wednesday. The biotech's shares are extending yesterday's rally following a positive top-line data readout for mirvetuximab as a treatm...

3 Penny Stocks to Watch in December That Exploded Today If you’re looking for penny stocks that could explode or have exploded, there are plenty of options to choose from. But, to pick the best penny stocks to buy , investors need to have a thorough understanding of what ...

Gainers: Arbutus Biopharma (NASDAQ:ABUS) +47%. Ardelyx (NASDAQ:ARDX) +31%. Context Therapeutics (NASDAQ:CNTX) +19%. ImmunoGen (NASDAQ:IMGN) +17%. Skylight Health Group (NASDAQ:SLHG) +16%. Losers: BeyondSpring (NASDAQ:BYSI) -53%. Aditxt (NASDAQ:ADTX) -25%. CTI (NASDAQ:CTIC)...